Industry Leaders to Discuss the Transformative Shift from Recreational Cannabis to Pharmaceutical Applications
LITTLETON, Colo. and CHICAGO, June 3, 2025 /PRNewswire/ — DeFloria, Inc., the botanical-drug developer advancing the first of its kind AJA001 oral solution for autism spectrum disorder (ASD), today announced it will be featured in a high-profile investor panel at the Benzinga Cannabis Capital Conference in Chicago on June 9th. Presented by AJNA BioSciences and Charlotte’s Web (TSX: CWEB) (OTCQX: CWBHF), the session, “Evolving from Dispensaries to Pharmacies: Investing in the Future of Cannabis,” will examine the multi-billion-dollar inflection point as cannabis investment migrates from the retail shelf to the prescription pad.
Global market forecasts project a dramatic shift from today’s recreational-dominated market to a trillion-dollar pharmaceutical-centric future within the next decade1. This shift represents the next…
